These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1728761)

  • 21. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S; Bryant SG; Kluge RM
    Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.
    Coplan PM; Noel RA; Levitan BS; Ferguson J; Mussen F
    Clin Pharmacol Ther; 2011 Feb; 89(2):312-5. PubMed ID: 21160469
    [No Abstract]   [Full Text] [Related]  

  • 25. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse drug reaction monitoring in pediatric practice.
    Kshirsagar NA; Karande S
    Indian Pediatr; 1996 Dec; 33(12):993-8. PubMed ID: 9141798
    [No Abstract]   [Full Text] [Related]  

  • 27. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 28. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 29. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 30. Issues in bringing new drugs to the market.
    Ansbacher R
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16322437
    [No Abstract]   [Full Text] [Related]  

  • 31. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.
    Faich GA; Castle W; Bankowski Z
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The safety of drugs].
    de Cea Lavech de Chancy H
    Rev Clin Esp; 1990 Sep; 187(4):184-90. PubMed ID: 2091076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reporting drug product defects--JCAHO.
    Hoffmann RP
    Hosp Pharm; 1989 Feb; 24(2):143-4. PubMed ID: 10318199
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety in clinical trials.
    Wallander MA
    Scand J Prim Health Care Suppl; 1990; 1():89-91. PubMed ID: 2100372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Eighth French Drug Surveillance Seminar. Paris, 23-24 October 1986].
    Therapie; 1987; 42(4):331-410. PubMed ID: 3686465
    [No Abstract]   [Full Text] [Related]  

  • 36. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
    Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
    [No Abstract]   [Full Text] [Related]  

  • 37. [Drug surveillance: the concept, the need and methods].
    Moreno González A
    An R Acad Nac Med (Madr); 1992; 109(1):197-218; discussion 218-20. PubMed ID: 1463138
    [No Abstract]   [Full Text] [Related]  

  • 38. [Is imputation in drug surveillance reliable?].
    Girard M
    Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
    [No Abstract]   [Full Text] [Related]  

  • 39. [6th French seminar on drug surveillance. Clermont-Ferrand, 22-23 November 1984].
    Therapie; 1985; 40(5):287-376. PubMed ID: 4095682
    [No Abstract]   [Full Text] [Related]  

  • 40. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.